Skip to main content
SpringerLink
Log in

TAF statt TDF

Neue Therapie schont die Niere

New therapy preservers the kidney

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Tenofovir ist als ein zentraler Baustein der HIV-Therapie sehr häufig im Einsatz. Doch die bisher verwendete Substanz führte nicht selten zu Nierenfunktionsstörungen. Ändert sich dies mit der Einführung eines neueren Präparats?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Nishijima T et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from10 years of follow-up, AIDS 2014, 28:1903–1910

    Article  CAS  PubMed  Google Scholar 

  2. Nelson M, Katlama C, Montaner JS, et al. The safety of TDF for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273–81.

    Article  CAS  PubMed  Google Scholar 

  3. Gallant JE, Winston J, DeJesus E, et al. The 3- year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue- containing regime in antiretroviral- naive patients. AIDS 2008, 22:2155–2163.

    Article  CAS  PubMed  Google Scholar 

  4. Casado, Jose et al.: Prevalence and significance of proximal renal tubular abnormalities in HIV infected patients receiving tenofovir. Aids 2016, 30: 231–239

    Article  CAS  PubMed  Google Scholar 

  5. Martorell C, et al. Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide in Geriatric Adults with Renal Impairment, 7th International Workshop on HIV & Aging, September 26-27, 2016, Washington DC

  6. Raffi F, et al. HIV Drug Therapy Glasgow 2016. O125.

  7. Sax P, et al. Lancet 2014

  8. Ruane P, et al. J Acquir Immune Defic Syndr. 2013;63:449.

    Article  CAS  PubMed  Google Scholar 

Weiterführende Literatur

  • Gallant Joel E, Eric S Daar, Raffi, Francois et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016; 3: e158–65

    Article  PubMed  Google Scholar 

  • Gallant Joel E, Brunetta Jason, Crofoot Gordon et al. Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016; 73:294–298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gallant JE, Parish MA, et al. Tenofovir and changes in renal function:reply to Gupta (letter). Clin Infect Dis 2005; 41:571

    Article  Google Scholar 

  • Gaur Aditya H, Kizito Hilda, Prasitsueubsai Wasana et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naïve, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV 2016, Published online October 17,2016 hhtp://dx.doi.org/10.1016/S2352-3018(16)30121-7

  • Huhn Gregory D, Tebas Pablo, Galland Joel et al. A Randomized, Opel-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIB-1-Infected Adults. J Acquir Immune Defic Syndr, Volume 74,Number 2, February 1,2017

  • Mills Anthony, Arribas Jose R, Andrade-Villanueva Jaime et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomized active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2015, Published online, November 2, 2015; http://dx.doi.org/10.1016/ S1473-3099(15)00348-5

  • Post Frank A, Tebas Pablo, Clarke Amanda et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr; Volume 74; Number 2, February 1, 2017

  • Pozniak Anton, Arribad Jose R, Gathe Joseph et al. Switching to Tenofovir Alafenamide, Coformulataed With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr; Volume 71; Number 5, April 15,2016

  • Raffi F et al. Long-term (96-week) Efficacy and Safety After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in HIV-infected, Virologically Suppressed Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print

  • Rieke, A. HIV und Niere in www.HIVBUCH.de, 2016; 552- 565

  • Sax Paul E, Wohl, David, Yin Michael T et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606–15

    Article  CAS  PubMed  Google Scholar 

  • Wohl David, Oka Shinichi, Clumeck Nathan et al. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr 2016; 72:58–64

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrologie/Infektiologie, Gemeinschaftsklinikum Mittelrhein, Kemperhof Koblenz, Koblenzer Str. 115–155, D-56073, Koblenz, Deutschland

    Ansgar Rieke

Authors
  1. Ansgar Rieke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ansgar Rieke.

Additional information

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rieke, A. Neue Therapie schont die Niere. MMW - Fortschritte der Medizin 159 (Suppl 2), 27–31 (2017). https://doi.org/10.1007/s15006-017-9731-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9731-1

Keywords

Search

Navigation